Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.

ABSTRACT:

Background

Emerging evidence indicates that RUNX3 is a candidate tumor suppressor in several types of human tumors, including non-small cell lung cancer (NSCLC). However, the correlation between RUNX3 hypermethylation and clinicopathological characteristics of NSCLC remains unclear. Here, we conducted a systematic review and meta-analysis to quantitatively evaluate the effects of RUNX3 hypermethylation on the incidence of NSCLC and clinicopathological characteristics.

Methods

A detailed literature search was made using Medline, Embase and Web of Science for related research publications written in English. The methodological quality of the studies was evaluated. The data were extracted and assessed independently by two reviewers. Analysis of pooled data was performed. The od

SUBMITTER: Xu L 

PROVIDER: S-EPMC4461130 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature